Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6556 | Ordered by Date (descending)
1 2 3 ... 64 65 66  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED 2023-01-24
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-19
Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems 2023-01-18
Blackford Analysis–Bayer: investment, 202301– acquisition by Bayer ANNOUNCED 2023-01-18
Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems 2023-01-18
Flame Biosciences–Leap Therapeutics: investment, 202301 merger acquisition of Flame Biosciences Inc by Leáp Therapeutics Inc 2023-01-17
InDevR–Adjuvant Capital: investment, 202301 financing round Series B totalling $9m incl $4m from Adjuvant Capital 2023-01-17
InDevR–Mérieux: investment, 202301 financing round Series B totalling $9m incl $5m from bioMérieux in connection w partnership 2023-01-17
InDevR–SEVERAL: investment, 202301 financing round Series B $9m from bioMérieux + Adjuvant Capital 2023-01-17
Mérieux–InDevR: VaxArray platform, 202301– excl distribution of VaxArray portfolio by bioMérieux in Europe 2023-01-17
Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery 2023-01-11
NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer 2023-01-10
NextPoint Therapeutics–Catalio Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Catalio Capital Management 2023-01-10
NextPoint Therapeutics–Harvard Univ: investment, 202301 financing round Series B totalling $80m incl existing + co-investor Binney Street Capital 2023-01-10
NextPoint Therapeutics–Invus Group: investment, 202301 financing round Series B totalling $80m incl new + co-investor Invus 2023-01-10
NextPoint Therapeutics–MPM Capital: investment, 202301 financing round Series B totalling $80m incl existing + co-investor MPM Capital Management 2023-01-10
NextPoint Therapeutics–PagodaTree Partners: investment, 202301 financing round Series B totalling $80m incl new + co-investor PagodaTree Partners 2023-01-10
NextPoint Therapeutics–PERSON: investment, 202301 financing round Series B totalling $80m incl existing + co-investor + co-founder Gordon Freeman 2023-01-10
NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures 2023-01-10
NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures 2023-01-10
NextPoint Therapeutics–Sixty Degree Capital: investment, 202301 financing round Series B totalling $80m incl new + co-investor Sixty Degree Capital 2023-01-10
Albireo–Ipsen: investment, 202301– cash tender offer $952m at $42/share plus 1 CVR/share entitling to $10/CVR 2023-01-09
Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 2023-01-09
Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea 2023-01-09
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO 2023-01-09
Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash 2023-01-09
Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED 2023-01-08
Synthekine–Column Group: investment, 202301 financing round round Series C totalling $100m incl existing + lead investor The Column Group 2023-01-06
Synthekine–SEVERAL: investment, 202301 financing round round Series C $100m led by The Column Group with new + existing investors 2023-01-06
Acquifer Imaging–Bruker: investment, 202201 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker 2023-01-05
Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners 2023-01-05
Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute 2023-01-05
Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners 2023-01-05
Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP 2023-01-05
Asimov–Andreessen Horowitz: investment, 202301 financing round Series B totalling $175m incl existing + co-investor a16z 2023-01-05
Asimov–Casdin Capital: investment, 202301 financing round Series B totalling $175m incl co-investor Casdin Capital 2023-01-05
Asimov–CPPIB: investment, 202301 financing round Series B totalling $175m incl lead investor CPP Investments 2023-01-05
Asimov–Fidelity: investment, 202301 financing round Series B totalling $175m incl co-investor Fidelity Management and Research Company 2023-01-05
Asimov–Horizon Ventures: investment, 202301 financing round Series B totalling $175m incl existing + co-investor Horizon Ventures 2023-01-05
Asimov–KdT Ventures: investment, 202301 financing round Series B totalling $175m incl co-investor KDT 2023-01-05
Asimov–Pillar: investment, 202301 financing round Series B totalling $175m incl co-investor Pillar 2023-01-05
Asimov–SEVERAL: investment, 202301 financing round Series B $175m led by CPP Investments 2023-01-05
BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m 2023-01-05
Volta Medical–Gilde Investment: investment, 202301 fianncing round Series B totalling €36m incl existing + co-investor Gilde Healthcare 2023-01-05
Volta Medical–Lightstone Ventures: investment, 202301 fianncing round Series B totalling €36m incl new + co-investor Lightstone Ventures 2023-01-05
Volta Medical–SEVERAL: investment, 202301 fianncing round Series B €36m led by Vensana Capital 2023-01-05
Volta Medical–Vensana Capital: investment, 202301 fianncing round Series B totalling €36m incl new + lead investor Vensana Capital 2023-01-05
Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker 2023-01-04
Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties 2023-01-04
Cellectis–EU (govt): credit, 202212– credit facility up to €40m in 3 tranches from EIB to develop allogeneic CAR T-cell products 2022-12-28
Merck (US)–Kelun Pharmaceuticals: antibody-drug conjugates, 202212– collab + license ww excl $175m upfront + $9.3b milestones for 7 ADCs for cancer 2022-12-22
Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED 2022-12-22
Ganymede Bio–Caffeinated Capital: investment, 202212 financing round Series A totalling $12.75m incl lead investor Caffeinated Capital 2022-12-20
Ganymede Bio–SEVERAL: investment, 202212 financing round Series A $12.75m led by Caffeinated Capital 2022-12-20
Tmunity Therapeutics–Gilead: investment, 202212– acquisition €na excluding PSMA + PSCA assets by Kite ANNOUNCED 2022-12-20
Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties 2022-12-19
Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures 2022-12-15
Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI 2022-12-14
Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures 2022-12-14
Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC 2022-12-14
BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures 2022-12-13
BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures 2022-12-13
BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health 2022-12-13
BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises 2022-12-13
BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises 2022-12-13
BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital 2022-12-13
BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures 2022-12-13
Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand 2022-12-13
Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share 2022-12-12
MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM 2022-12-08
Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices 2022-12-06
Entact Bio–SEVERAL: investment, 202212 financing round Series A $81m co-led by Qiming Venture Partners USA + venBio Partners 2022-12-06
Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck 2022-12-01
Intellia Therapeutics–SEVERAL: investment, 202211–202212 public offering $300m+$45m with 6.55m+983k shares at $45.8/share 2022-11-30
BMS–Envisagenics: AI-based drug discovery, 202211– collab multi-year using SpliceCore AI platform to discover new oncology targets 2022-11-29
Cajal Neuroscience–Alexandria Real Estate: investment, 202211 financing round Series A totalling $96m incl co-investor Alexandria Venture Investments 2022-11-29
Cajal Neuroscience–BMS: investment, 202211 financing round Series A totalling $96m incl co-investor BMS 2022-11-29
Cajal Neuroscience–Column Group: investment, 202211 financing round Series A totalling $96m incl co-lead investor The Column Group 2022-11-29
Cajal Neuroscience–Dolby Family Ventures: investment, 202211 financing round Series A totalling $96m incl co-investor Dolby Family Ventures 2022-11-29
Cajal Neuroscience–Evotec: investment, 202211 financing round Series A totalling $96m incl existing + co-investor Evotec 2022-11-29
Cajal Neuroscience–Lux Capital: investment, 202211 financing round Series A totalling $96m incl co-lead investor Lux Capital 2022-11-29
Cajal Neuroscience–SEVERAL: investment, 202211 financing round Series A $96m led by The Column Group + Lux Capital 2022-11-29
Cajal Neuroscience–Ten Bridge Communications: public relations, 202211 service existent Ten Bridge is media contact 2022-11-29
Cajal Neuroscience–Two Sigma Ventures: investment, 202211 financing round Series A totalling $96m incl co-investor Two Sigma Ventures 2022-11-29
Focus-X Therapeutics–Full-Life Technologies: investment, 202211– acquisition up to $245m of Focux-X by Full-Life Technologies ANNOUNCED 2022-11-29
Genezen–Ramarketing: public relations, 202211 service existent Ramarketing is media contact 2022-11-29
Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis 2022-11-29
Rgenta Therapeutics–AstraZeneca: investment, 202211 financing round Series A totalling $52m incl new + lead investor AZ-CICC Fund 2022-11-29
Rgenta Therapeutics–Delos Capital: investment, 202211 financing round Series A totalling $52m incl new + co-investor Delos Capital 2022-11-29
Rgenta Therapeutics–Korean Investment Partners: investment, 202211 financing round Series A totalling $52m incl new + co-investor Korean IP 2022-11-29
Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund 2022-11-29
Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform 2022-11-29
Biomemory–SEVERAL: investment, 202211 seed financing round €5m led by eureKARE + French Tech Seed Fund 2022-11-28
Strand Therapeutics–FPV Ventures: investment, 202211 financing round Series A extension totalling $45m incl new + lead investor VPF Ventures 2022-11-28
Strand Therapeutics–KKH Advisors: public relations, 202211 service existent by KKH Advisors 2022-11-28
Strand Therapeutics–Lilly: investment, 202211 financing round Series A extension totalling $45m incl new + co-investor Eli Lilly 2022-11-28
Strand Therapeutics–OTHER: investment, 202211 financing round Series A extension totalling $45m incl undisclosed syndicate 2022-11-28
Strand Therapeutics–Playground Global: investment, 202211 financing round Series A extension totalling $45m incl existing + co-investor PG 2022-11-28
Strand Therapeutics–Potentum Partners: investment, 202211 financing round Series A extension totalling $45m incl new + co-investor Potentum Partners 2022-11-28
Strand Therapeutics–SEVERAL: investment, 202211 financing round Series A extension $45m led by FPV Ventures bringing total round to $97m 2022-11-28
1 2 3 ... 64 65 66  next pagenext page



Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px

» top